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CD4+CD25+ Tregs are a suppressive subset of CD4+ T helper cells important for the regulation of immune 
responses. Tregs are proven highly effective in preventing graft versus host disease (GVHD) and autoimmunity 
in murine models. The relative frequency of Tregs in peripheral blood is approximately 1-2% of total 
lymphocytes implicating the necessity of ex vivo expansion of Tregs prior to adoptive transfer for most clinical 
applications. The Dynabeads™ CD3⁄CD28 CTS™ has been developed for ex vivo isolation, activation, and 
expansion of human T cells for use in various immunotherapies. To address the specific needs for Treg 
expansion, we have generated a new product, Dynabeads™ Treg CD3/CD28, designed to provide optimal 
activation and expansion of Tregs. We have compared the functionality of Dynabeads™Treg CD3/CD28 with 
other existing technologies (competitors and Dynabeads™ CD3⁄CD28 CTS™) regarding expansion of 
CD4+CD25+CD127low flow sorted Tregs and magnetically isolated Tregs. Our studies demonstrate superior 
fold expansion of functional Tregs with the Dynabeads™ Treg CD3/CD28. We show several hundred fold 
expansion of Treg cells in 14 days culture and with maintenance of high FOXP3 expression and 
suppressive activity. This optimized Dynabeads™ Treg CD3/CD28 support consistent and scalable Treg 
manufacturing for immunotherapies, supplementing our Cell Therapy System (CTSTM) portfolio.  
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